Zurück zu Projekte

14011.2 PFLS-LS

14011.2 PFLS-LS

Zusammenfassung

Development of an organotypic high-throughput screening assay kit to determine predictability of anti-cancer drugs in 3D QGel

Weitere Texte

Abstract

This project brings together the start-up company QGel and academic cancer and matrix|biology experts in order to develop proven QGel technology into a 3D cell-based highthroughput|assay kit for primary patient-derived cancer cells. Commercially available anticancer|drugs will be tested on these tumor models grown in vitro with QGel technology.|Based on indications by cancer experts, QGel drug-tumor response data are collected and|compared to clinical data of these drugs.

Beteiligte

Colin Sanctuary

Wirtschaftspartner

colin.sanctuary@qgelbio.com

QGel SA Colin Sanctuary Bâtiment C / EPFL Innovation Park 1015 Lausanne VD CH

Matthias Lutolf

Kontaktperson

matthias.lutolf@epfl.ch

EPFL SV IBI LSCB Matthias Lutolf Station 15, Bâtiment Al 1109 1015 Lausanne VD CH

Projektdetails

Forschungsstelle
INNOSUISSE
Projektstatus
Abgeschlossen
Projekttyp
Forschungsprojekt
Startdatum
2013-05-31
Enddatum
2017-03-31
Bewilligte Gesamtkosten
CHF 395600.00
Sektion
20 Förderbereich Life Sciences
NABS Politikbereich
Industrielle Produktivität und Technologie

Forschungsdisziplinen

  • P004 Biochemistry, Metabolism 100.0%